首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   930859篇
  免费   67535篇
  国内免费   1340篇
耳鼻咽喉   12959篇
儿科学   24378篇
妇产科学   23236篇
基础医学   132945篇
口腔科学   28256篇
临床医学   80554篇
内科学   183274篇
皮肤病学   19228篇
神经病学   72254篇
特种医学   36799篇
外国民族医学   79篇
外科学   152085篇
综合类   18043篇
现状与发展   1篇
一般理论   234篇
预防医学   61738篇
眼科学   21309篇
药学   72557篇
  3篇
中国医学   2162篇
肿瘤学   57640篇
  2018年   8962篇
  2017年   7027篇
  2016年   7768篇
  2015年   8859篇
  2014年   11990篇
  2013年   17502篇
  2012年   24090篇
  2011年   25055篇
  2010年   14808篇
  2009年   14272篇
  2008年   24625篇
  2007年   25699篇
  2006年   26496篇
  2005年   25434篇
  2004年   24572篇
  2003年   23615篇
  2002年   23157篇
  2001年   54729篇
  2000年   56544篇
  1999年   46952篇
  1998年   10735篇
  1997年   9471篇
  1996年   9594篇
  1995年   8927篇
  1994年   8279篇
  1993年   7597篇
  1992年   35491篇
  1991年   33915篇
  1990年   32737篇
  1989年   31873篇
  1988年   28998篇
  1987年   28253篇
  1986年   26290篇
  1985年   25147篇
  1984年   17834篇
  1983年   15146篇
  1982年   7796篇
  1981年   6772篇
  1979年   15783篇
  1978年   10600篇
  1977年   9052篇
  1976年   7873篇
  1975年   8628篇
  1974年   10467篇
  1973年   9859篇
  1972年   9358篇
  1971年   8852篇
  1970年   8428篇
  1969年   7924篇
  1968年   7201篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
992.
PURPOSE: The use of gefitinib, the first drug approved to inhibit the epidermal growth factor receptor tyrosine kinase, is indicated in patients with non-small-cell lung cancer with tumors progressive after chemotherapy. The unique mechanism of action of this agent leads to distinctive patterns of response and toxicity in persons with lung cancer. Many of the principles of management relevant to gefitinib are distinct from those with conventional cytotoxic drugs. To meet this need, we present practical guidelines on the use of gefitinib in patients with non-small-cell lung cancer. METHODS: This article reviews gefitinib's indications, dosing, response phenomena, and patterns of relapse in individuals with radiographic response. RESULTS: We present our recommendations for the management of rash and diarrhea caused by this agent. CONCLUSION: This information can guide practitioners and help them inform their patients about what to expect when they receive gefitinib.  相似文献   
993.
BACKGROUND: The impact of exercise programmes for heart failure on those close to the patient is largely unknown. We examined the effect of a hospital and home-based exercise intervention on burden, anxiety and depression of informal caregivers. DESIGN: The study was a randomized, controlled trial. Heart failure patients were randomized to a seated 12-week hospital-based exercise programme. Caregiver measures were gathered at baseline, 3 months later and 6 months following baseline. METHODS: Sixty caregivers (mean age 63.4 years, 65% female) of heart failure patients (n = 82, mean age 80.5 years, 44% female) participating in a trial of an exercise intervention were recruited. Caregiver burden, anxiety and depression were assessed. RESULTS: There were no differences in caregiver burden, depression or anxiety between the two groups of caregivers at baseline (caregiver burden, patient control 33.1 versus patient exercise 34.1; anxiety 4.1 versus 5.5; depression 2.8 versus 3.8). At 3 months there were no differences between caregivers in the two groups on outcomes. At 6-month follow-up caregivers of heart failure patients in the exercise group had burden scores that were significantly worse than the control group. There were no differences between the carers of exercise and control groups in anxiety and depression. Levels of anxiety and depression in the entire carer sample were marginally higher than reference values in a healthy non-clinical sample. CONCLUSION: The present exercise interventions for frail older patients did not benefit caregivers and was associated with an increase in caregiver burden. We suggest that future exercise interventions for heart failure patients should actively incorporate informal caregivers into research designs.  相似文献   
994.
995.
996.
997.
998.
999.
1000.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号